Seagen Inc

$171.43 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Seagen Inc

Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA or tucatinib, for treatment of certain metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancers. The Company is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its pipeline includes ladiratuzumab vedotin, an antibody-drug conjugate (ADC) targeting LIV-1.

Stock Analysis

last close $171.43
1-mo return 1.3%
3-mo return 19.6%
avg daily vol. 744.51T
52-week high 202.6
52-week low 133.2
market cap. $31.4B
forward pe -
annual div. -
roe 22.9%
ltg forecast -
dividend yield -
annual rev. $2.4B
inst own. 90.4%

Subscribe now for daily local and international financial news